The U.S. FDA authorized label revisions to Pfizer Inc.'s Chantix.
The pharma giant is no longer required to make boxed warnings regarding serious neuropsychiatric events that lead to anxiety and depression.
Chantix is a prescription medication that helps adults 18 and over to quit smoking. The treatment is considered superior to bupropion or nicotine patches.
The revision may further encourage smokers and healthcare providers to discuss smoking cessation treatment options, Pfizer said in a statement.